Abstract | BACKGROUND: METHODS: We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. RESULTS: Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). CONCLUSIONS:
|
Authors | Raffaele Landolfi, Roberto Marchioli, Jack Kutti, Heinz Gisslinger, Gianni Tognoni, Carlo Patrono, Tiziano Barbui, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 350
Issue 2
Pg. 114-24
(Jan 08 2004)
ISSN: 1533-4406 [Electronic] United States |
PMID | 14711910
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2004 Massachusetts Medical Society |
Chemical References |
- Platelet Aggregation Inhibitors
- Aspirin
|
Topics |
- Aspirin
(administration & dosage, adverse effects, therapeutic use)
- Cardiovascular Diseases
(epidemiology, mortality)
- Disease-Free Survival
- Double-Blind Method
- Female
- Hemorrhage
(chemically induced)
- Humans
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Polycythemia Vera
(complications, drug therapy)
- Risk Factors
- Thrombosis
(etiology, prevention & control)
|